228 related articles for article (PubMed ID: 18076711)
1. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
[TBL] [Abstract][Full Text] [Related]
2. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.
Mori N; Ishikawa C; Senba M; Kimura M; Okano Y
Biochem Pharmacol; 2011 May; 81(9):1106-15. PubMed ID: 21371446
[TBL] [Abstract][Full Text] [Related]
3. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
[TBL] [Abstract][Full Text] [Related]
5. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
Libertini S; Abagnale A; Passaro C; Botta G; Barbato S; Chieffi P; Portella G
Endocr Relat Cancer; 2011 Feb; 18(1):129-41. PubMed ID: 21071467
[TBL] [Abstract][Full Text] [Related]
6. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.
Wilkinson RW; Odedra R; Heaton SP; Wedge SR; Keen NJ; Crafter C; Foster JR; Brady MC; Bigley A; Brown E; Byth KF; Barrass NC; Mundt KE; Foote KM; Heron NM; Jung FH; Mortlock AA; Boyle FT; Green S
Clin Cancer Res; 2007 Jun; 13(12):3682-8. PubMed ID: 17575233
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
8. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
[TBL] [Abstract][Full Text] [Related]
12. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.
Tomita M; Tanaka Y; Mori N
Int J Cancer; 2010 Oct; 127(7):1584-94. PubMed ID: 20091867
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.
Manfredi MG; Ecsedy JA; Meetze KA; Balani SK; Burenkova O; Chen W; Galvin KM; Hoar KM; Huck JJ; LeRoy PJ; Ray ET; Sells TB; Stringer B; Stroud SG; Vos TJ; Weatherhead GS; Wysong DR; Zhang M; Bolen JB; Claiborne CF
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4106-11. PubMed ID: 17360485
[TBL] [Abstract][Full Text] [Related]
15. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
16. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
[TBL] [Abstract][Full Text] [Related]
17. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
Nair JS; de Stanchina E; Schwartz GK
Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
[TBL] [Abstract][Full Text] [Related]
18. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
19. Validating Aurora B as an anti-cancer drug target.
Girdler F; Gascoigne KE; Eyers PA; Hartmuth S; Crafter C; Foote KM; Keen NJ; Taylor SS
J Cell Sci; 2006 Sep; 119(Pt 17):3664-75. PubMed ID: 16912073
[TBL] [Abstract][Full Text] [Related]
20. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
